The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
NeuroOne Medical Technologies Corp (NASDAQ: NMTC) closed the day trading at $0.91 up 0.78% from the previous closing price of $0.9. In other words, the price has increased by $0.78 from its previous closing price. On the day, 0.54 million shares were traded. NMTC stock price reached its highest trading level at $0.9548 during the session, while it also had its lowest trading level at $0.8751.
Ratios:
For a better understanding of NMTC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.80 and its Current Ratio is at 7.13. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on May 05, 2025, initiated with a Buy rating and assigned the stock a target price of $1.45.
On March 29, 2022, Craig Hallum Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $6 to $2.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 05 ’25 when Christianson Mark sold 30,000 shares for $0.74 per share. The transaction valued at 22,203 led to the insider holds 231,238 shares of the business.
Christianson Mark bought 30,000 shares of NMTC for $24,210 on Aug 20 ’25. On Jun 04 ’25, another insider, Christianson Mark, who serves as the Business Development Director of the company, sold 10,000 shares for $0.58 each. As a result, the insider received 5,804 and left with 261,491 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NMTC now has a Market Capitalization of 45349564 and an Enterprise Value of 37605596. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.71 while its Price-to-Book (P/B) ratio in mrq is 5.53. Its current Enterprise Value per Revenue stands at 5.673 whereas that against EBITDA is -6.95.
Stock Price History:
The Beta on a monthly basis for NMTC is 0.60, which has changed by -0.02577871 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, NMTC has reached a high of $1.39, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is 5.95%, while the 200-Day Moving Average is calculated to be 8.80%.
Shares Statistics:
Over the past 3-months, NMTC traded about 387.62K shares per day on average, while over the past 10 days, NMTC traded about 670120 shares per day. A total of 49.82M shares are outstanding, with a floating share count of 44.07M. Insiders hold about 11.87% of the company’s shares, while institutions hold 42.10% stake in the company. Shares short for NMTC as of 1759190400 were 56855 with a Short Ratio of 0.15, compared to 1756425600 on 185564. Therefore, it implies a Short% of Shares Outstanding of 56855 and a Short% of Float of 0.11999999.
Earnings Estimates
. The current market rating for NeuroOne Medical Technologies Corp (NMTC) reflects the collective analysis of 2 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.03 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.1 and -$0.13 for the fiscal current year, implying an average EPS of -$0.12. EPS for the following year is -$0.14, with 2.0 analysts recommending between -$0.14 and -$0.15.
Revenue Estimates
For the next quarter, 2 analysts are estimating revenue of $2.69M. There is a high estimate of $2.98M for the next quarter, whereas the lowest estimate is $2.4M.
Based on 2 analysts’ estimates, the company’s revenue will be $11.26M in the next fiscal year. The high estimate is $12.4M and the low estimate is $10.11M.
